Consumers now have the opportunity to purchase Exact Sciences’ latest liquid biopsy early detection test, Cancerguard, to determine if they may be at risk for one of the 50 different types of cancers included in the test’s analysis. The biotechnology company officially launched the test on Wednesday, and Tom Beer, Exact’s chief medical officer, expressed his excitement about the news.
“I am absolutely thrilled. This is exactly why I joined Exact,” Beer shared. As a practicing oncologist, Beer emphasized the importance of catching cancer in its early stages, highlighting the significant impact it can have on patient outcomes. Liquid biopsy tests like Cancerguard have the potential to revolutionize cancer detection by focusing on a wide range of cancers beyond the commonly screened types such as breast, prostate, colorectal, lung, and cervical cancer.
“We are not just introducing a test, we are ushering in a new era in cancer early detection. While it’s still early days, I believe that in a decade from now, we will look back at today and be astonished that we once only screened for a handful of cancers,” Beer stated confidently.
The launch of Cancerguard represents a significant step forward in the field of cancer detection and prevention. By providing individuals with a comprehensive analysis of their cancer risk, Exact Sciences aims to empower patients to take proactive steps towards early intervention and treatment. With the potential to detect a wide range of cancers at an early stage, Cancerguard has the potential to save countless lives and improve overall cancer outcomes.
The introduction of Cancerguard is a testament to Exact Sciences’ commitment to advancing cancer detection technology and improving patient care. As the medical community continues to make strides in early cancer detection, tests like Cancerguard offer hope for a future where cancer can be detected and treated more effectively than ever before.
